Eric S Zhou1,2, Alexis L Michaud1, Christopher J Recklitis1,2. 1. Perini Family Survivors' Center, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Insomnia is common among cancer survivors. Although behavioral treatments for insomnia are effective, access is limited. Stepped care delivery models may provide insomnia treatment that is more efficient and accessible to cancer survivors. METHODS:Fifty-one survivors (mean age, 55 years) with elevated Insomnia Severity Index (ISI) scores (≥12) first participated inSleep Training Education Program (STEP)-1: a single, sleep education session. Those reporting elevated ISI scores 1 month later were offered STEP-2: a 3-session, group cognitive behavioral treatment for insomnia that has been demonstrated to be efficacious. Participants were considered treatment responders if their ISI score improved by ≥6 points and were considered as having remitted if their posttreatment ISI score was <12. Mood was assessed with the Profile of Mood States-Short Form (POMS-SF). RESULTS: Following STEP-1, ISI scores improved (17.1 to 11.2; P < .001), with 45% responding and 41% remitted. Insomnia remission after STEP-1 was associated with lower insomnia severity and shorter duration of sleep problems at baseline. Of the 30 (59%) survivors with unremitted insomnia after STEP-1, 14 (47%) participated in STEP-2. Following STEP-2, ISI scores improved (16.9 to 8.8; P < .001), with 79% responding and 71% remitted. STEP-2 participation was associated with interest in sleep treatment at baseline, but not demographic/health-related variables. Mood improved significantly following both STEP-1 and STEP-2 (P < .001). CONCLUSION: A stepped care approach to treating insomnia among cancer survivors has the potential to improve treatment accessibility. A sizable proportion of survivors can benefit from 2 different low-intensity approaches that could be delivered by nonsleep specialists. For individuals who require more intensive care, assessing treatment interest can identify those who are likely to engage.
RCT Entities:
BACKGROUND:Insomnia is common among cancer survivors. Although behavioral treatments for insomnia are effective, access is limited. Stepped care delivery models may provide insomnia treatment that is more efficient and accessible to cancer survivors. METHODS: Fifty-one survivors (mean age, 55 years) with elevated Insomnia Severity Index (ISI) scores (≥12) first participated in Sleep Training Education Program (STEP)-1: a single, sleep education session. Those reporting elevated ISI scores 1 month later were offered STEP-2: a 3-session, group cognitive behavioral treatment for insomnia that has been demonstrated to be efficacious. Participants were considered treatment responders if their ISI score improved by ≥6 points and were considered as having remitted if their posttreatment ISI score was <12. Mood was assessed with the Profile of Mood States-Short Form (POMS-SF). RESULTS: Following STEP-1, ISI scores improved (17.1 to 11.2; P < .001), with 45% responding and 41% remitted. Insomnia remission after STEP-1 was associated with lower insomnia severity and shorter duration of sleep problems at baseline. Of the 30 (59%) survivors with unremitted insomnia after STEP-1, 14 (47%) participated in STEP-2. Following STEP-2, ISI scores improved (16.9 to 8.8; P < .001), with 79% responding and 71% remitted. STEP-2 participation was associated with interest in sleep treatment at baseline, but not demographic/health-related variables. Mood improved significantly following both STEP-1 and STEP-2 (P < .001). CONCLUSION: A stepped care approach to treating insomnia among cancer survivors has the potential to improve treatment accessibility. A sizable proportion of survivors can benefit from 2 different low-intensity approaches that could be delivered by nonsleep specialists. For individuals who require more intensive care, assessing treatment interest can identify those who are likely to engage.
Authors: Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-06-02 Impact factor: 508.702
Authors: Claudia Trudel-Fitzgerald; Eric S Zhou; Elizabeth M Poole; Xuehong Zhang; Karin B Michels; A Heather Eliassen; Wendy Y Chen; Michelle D Holmes; Shelley S Tworoger; Eva S Schernhammer Journal: Br J Cancer Date: 2017-03-30 Impact factor: 7.640
Authors: Astrid Lahousse; Eva Roose; Laurence Leysen; Sevilay Tümkaya Yilmaz; Kenza Mostaqim; Felipe Reis; Emma Rheel; David Beckwée; Jo Nijs Journal: J Clin Med Date: 2021-12-30 Impact factor: 4.241
Authors: Natalie L Wu; Amanda I Phipps; Kevin R Krull; Karen L Syrjala; Paul A Carpenter; Laura S Connelly-Smith; Mary E Flowers; Elizabeth F Krakow; Masumi Ueda Oshima; Stephanie J Lee; Eric J Chow Journal: Blood Adv Date: 2022-07-26
Authors: Mei Jun Tran; Michael Jefford; Ben Smith; Fiona Lynch; Haryana M Dhillon; Joanne Shaw; Lachlan McDowell; Alan White; Clare Halloran; David Wiesenfeld; Maria Ftanou Journal: Pilot Feasibility Stud Date: 2022-08-10
Authors: Emma Vaughan; Maria Ftanou; Jeremy Lewin; Andrew Murnane; Ilana Berger; Joshua F Wiley; Martha Hickey; Dani Bullen; Michael Jefford; Jeremy Goldin; Jeremy Stonehouse; Kate Thompson Journal: Pilot Feasibility Stud Date: 2022-07-28
Authors: Kai Spiegelhalder; Harald Baumeister; Dieter Riemann; David Daniel Ebert; Abdulwahab Al-Kamaly; Martina Bader; Natalie Bauereiss; Fee Benz; Lina Braun; Claudia Buntrock; Maike Burkhardt; Pim Cuijpers; Katharina Domschke; Patrick Dülsen; Marvin Franke; Lukas Frase; Elena Heber; Kathrin Helm; Terry Jentsch; Anna Johann; Ann-Marie Küchler; Michael Kuhn; Dirk Lehr; Andy Maun; Charles M Morin; Morten Moshagen; Kneginja Richter; Julian Schiel; Laura Simon; Lukas Spille; Hans-Günter Weeß Journal: BMJ Open Date: 2022-08-03 Impact factor: 3.006
Authors: Fiona A Lynch; Lynda Katona; Michael Jefford; Allan Ben Smith; Joanne Shaw; Haryana M Dhillon; Steve Ellen; Jo Phipps-Nelson; Julia Lai-Kwon; Donna Milne; Lahiru Russell; Victoria Dax; Justine Diggens; Holly Kent; Alison Button-Sloan; Jane Elliott; Mark Shackleton; Hayley Burridge; Maria Ftanou Journal: J Clin Med Date: 2020-09-14 Impact factor: 4.241